Intestinal Apolipoprotein A-IV Gene Transcription Is Controlled by Two Hormone-Responsive Elements: A Role for Hepatic Nuclear Factor-4 Isoforms
Amena Archer,
Dominique Sauvaget,
Valérie Chauffeton,
Pierre-Etienne Bouchet,
Jean Chambaz,
Martine Pinçon-Raymond,
Philippe Cardot,
Agnès Ribeiro and
Michel Lacasa
Unité Mixte de Recherche 505, Institut National de la Santé et de la Recherche Médicale-Université Pierre & Marie Curie, 75006 Paris, France
Address all correspondence and requests for reprints to: Agnès Ribeiro, Unité Mixte de Recherche 505 Institut National de la Santé et de la Recherche Médicale-Université Pierre & Marie Curie, 15 rue de lEcole de Médecine, 75006 Paris, France. E-mail: agnes.ribeiro-pillet-u505{at}bhdc.jussieu.fr.
 |
ABSTRACT
|
---|
In the small intestine, the expression of the apolipoprotein (apo) C-III and A-IV genes is restricted to the enterocytes of the villi. We have previously shown that, in transgenic mice, specific expression of the human apo C-III requires a hormone-responsive element (HRE) located in the distal region of the human apoA-IV promoter. This HRE binds the hepatic nuclear factors (HNF)-4
and
. Here, intraduodenal injections in mice and infections of human enterocytic Caco-2/TC7 cells with an adenovirus expressing a dominant-negative form of HNF-4
repress the expression of the apoA-IV gene, demonstrating that HNF-4 controls the apoA-IV gene expression in enterocytes. We show that HNF-4
and
functionally interact with a second HRE present in the proximal region of the human apoA-IV promoter. New sets of transgenic mice expressing mutated forms of the promoter, combined with the human apo C-III enhancer, demonstrate that, whereas a single HRE is sufficient to reproduce the physiological cephalo-caudal gradient of apoA-IV gene expression, both HREs are required for expression that is restricted to villi. The combination of multiple HREs may specifically recruit regulatory complexes associating HNF-4 and either coactivators in villi or corepressors in crypts.
 |
INTRODUCTION
|
---|
IN HUMANS, APOLIPOPROTEIN A-IV (apoA-IV) is synthesized by the small intestine. It is secreted with triacylglycerol-rich lipoproteins and is mostly associated with high-density lipoproteins in fasting human plasma. Although the precise function of apoA-IV is not known, in vivo evidence in animals supports its potential role in the control of food consumption, as well as in protection against atherosclerosis (for review see Refs.1, 2). Human genetic studies also show an inverse correlation between plasma apoA-IV levels and coronary lesions (3, 4). The human apoA-IV gene is located on chromosome 11, clustered with the apoA-I and apoC-III genes. Within the A-I/C-III/A-IV gene cluster, the apoA-I and A-IV genes are transcribed in the same direction, whereas the apoC-III gene is transcribed in the opposite direction. The apoC-III/A-IV intergenic region constitutes a common 6.6 kb 5'-flanking region for both genes (5). The intestinal expression of these apolipoproteins follows a decreasing gradient from the duodenum to the ileum (cephalo-caudal gradient) and is restricted to villi with a crypt to villus gradient (5, 6), setting these genes as selective markers of differentiated absorptive enterocytes.
The precise mechanisms involved in the regulation of the enterocyte differentiation program, based on a spatial restriction of the transcription of genes responsible for enterocyte functions, have not been determined. The intestinal expression of the human apoA-I and C-III genes requires a cooperation between their respective proximal hormone-responsive element (HRE) and a HRE located in the apoC-III enhancer. This has been demonstrated in vivo (7) and in vitro in hepatic HepG2 and enterocytic Caco-2 cell lines (8, 9, 10, 11, 12). Such a cooperation has also been reported in vitro between the HRE located in the apoC-III enhancer and the proximal (128/141) HRE of the human apoA-IV promoter (AIV-C) (13, 14), but its role in the enterocyte-specific expression of apoA-IV has not yet been tested in vivo. We have shown in transgenic mice that the human apoC-III enhancer is not sufficient to confer the spatial cephalo-caudal and crypt-villus gradients of expression to the genes of the A-I/C-III/A-IV cluster (15). Furthermore, we have recently identified a distal (357/ 377) HRE (AIV-E) in the human apoA-IV promoter that is necessary to confer the physiological pattern of apoA-IV gene expression in the intestine (16). Altogether, these results raise questions about the respective roles of the multiple HREs present in the apoA-I, C-III, and A-IV promoters in the restriction of the expression of apolipoprotein genes to villus enterocytes. In enterocytes, the distal HRE (AIV-E) of the apoA-IV promoter binds two distinct isoforms of hepatocyte nuclear factor 4 (HNF-4),
and
(16), which are encoded by two different genes (17, 18). Their intestinal pattern of expression led us to hypothesize that they could be involved in intestinal differentiation and regulation of gut-specific gene expression, as previously has been reported for several other transcription factors, e.g. cdx1, cdx2 (19, 20, 21), and the GATA 4, 5, 6 family (22, 23).
HNF-4
is a highly conserved member (NR2A1) of the nuclear receptor superfamily (24, 25). The presence of fatty acids in the ligand binding domain has been reported (26, 27), but the functional role of this association is still a matter of debate (28, 29, 30). The highest amounts of HNF-4
are found in the liver, the kidney, the intestine, and the pancreas in mammals and in the homologous structures in invertebrates (25, 31). HNF-4
is expressed in the primitive endoderm as soon as it becomes morphologically distinct and is important for its differentiation (32, 33). HNF-4
is not necessary for specification and early development of the liver (34). However, Hnf-4
-/ hepatoblasts fail to become mature hepatocytes, so this differentiation process requires HNF-4
(35, 36). The phenotype of a conditional knockout of Hnf-4
indicates that HNF-4
is also central to the maintenance of differentiated hepatocytes and acts in vivo as a major hepatic regulator of genes involved in the control of lipid metabolism, e.g. apoB, C-II, C-III, A-II, and A-IV genes (37). The function of the recently identified HNF-4
has not yet been clearly established (17, 18).
The aim of the present study was to demonstrate the role of HNF-4 in the intestinal expression of the apoA-IV gene and to determine the respective importance of the two HREs of the human apoA-IV promoter in its spatial pattern of expression. Using an adenovirus encoding a dominant-negative form of HNF-4
, we showed that HNF-4 controls the intestinal expression of the apoA-IV gene in mouse models in vivo, and in human enterocytic Caco-2/TC7 cells. Finally, we characterized the properties of HNF-4
and
binding to both HREs, and demonstrated in vivo, with transgenic mice, that both HREs are essential, in combination with the apoC-III enhancer, for the villus-specific expression of the apoA-IV gene.
 |
RESULTS
|
---|
A Dominant-Negative Form of HNF-4
Decreases apoA-IV Gene Expression in Vivo in Murine Small Intestine and ex Vivo in Caco-2/TC7 Cells
To investigate the role of HNF-4
and
isoforms in intestinal apoA-IV gene expression, we used a dominant-negative form of HNF-4
lacking the F region and the AF-2 activation domain (38). The dominant-negative HNF-4
(DN-HNF4
) binds to DNA as a dimer and inhibits the HNF-4
activity either by heterodimerization with the endogenous HNF-4
or by competitive binding to the HREs (38). We therefore investigated the functional role of the dominant-negative HNF-4
on the transactivation of the human apoA-IV promoter by HNF-4
(Fig. 1A
). We transiently transfected COS-7 cells with increasing amounts of the dominant-negative HNF-4
, a constant amount of HNF-4
(or HNF-4
as a control), and the chloramphenicol acetyltransferase (CAT) reporter gene under the control of the human apo A-IV promoter. Stimulation of the promoter by either HNF-4
or HNF-4
was similarly inhibited by the dominant-negative HNF-4
in a dose-dependent manner (Fig. 1A
). Thus, the dominant-negative HNF-4
impaired the transactivation activities of HNF-4
and HNF-4
.
We then generated an adenovirus expressing this dominant-negative HNF-4
to transduce human Caco-2/TC7 cells. These cells differentiate spontaneously after confluence into enterocytic cells, representative of small intestine enterocytes. The apo A-IV gene is not expressed in dividing Caco-2/TC7 cells but is expressed after they have differentiated. Dose-response (Fig. 1B
) and time-course experiments (Fig. 1C
) were thus performed on confluent cells using the dominant-negative HNF-4
or an adenovirus expressing GFP (the green fluorescent protein) (Ad-GFP) as a control. As a control, we used RT-PCR to check that the dominant-negative HNF-4
was transcribed in transduced Caco2/TC7 cells (Fig. 1B
, inset). The sequence of the reverse primer used to detect this mRNA is absent in the endogenous HNF-4 mRNA; it is only present in the cloning vector and thus specific for the truncated HNF-4 (Table 1
). At 5 d after infection, we observed a dose-dependent decrease in the apoA-IV mRNA level, with an 80% reduction at 50 pfu/cell (Fig. 1B
). Adenovirus-mediated expression of the dominant-negative HNF-4
reduced the level of apoA-IV mRNA after 2 d, and this inhibition was still observed 5 d after infection (Fig. 1C
). The specific effect of the dominant-negative HNF-4
was also assessed by measuring L19 mRNA levels. As expected, the mRNA levels of this large ribosomal polypeptide were not affected by the dominant-negative HNF-4
(Fig. 1D
). Conversely, the dominant-negative HNF-4
induced a 60% decrease in the mRNA levels of apoB (Fig. 1D
), a gene involved in lipid metabolism and known to be repressed in mice hepatocytes lacking HNF-4
(37).
Intestinal gene transfer was achieved by intraluminal injection in mice. In our experimental conditions, adapted from previous studies in rats (40), 5 d after an intraluminal injection of an adenovirus expressing the luciferase gene under the control of a cytomegalovirus promoter, luciferase activity was detected in the epithelial cells of the first segment of the small intestine, close to the injection point (not shown). Similarly, in mice that received a GFP-encoding adenovirus (Ad-GFP), fluorescence was clearly detectable in the villus epithelium and in crypts 5 d after injection (Fig. 2A
). The complete renewal of the intestinal epithelium from stem cells located in the crypts takes 34 d in mice. Because both GFP fluorescence and luciferase activities were still detectable 9 d after in vivo gene transfer (not shown), the stem cells of crypts must have been infected. Validated in this way, we applied this adenoviral strategy to the expression of the dominant-negative HNF-4
in mouse intestine. After intestinal injection, we first used RT-PCR to verify the expression of the dominant-negative HNF-4
mRNA in epithelial cells. Specificity was confirmed by the lack of any RT-PCR product in the sample from control mice injected with the Ad-GFP construction (Fig. 2B
, inset). As shown in Fig. 2B
, the expression of the dominant-negative form of HNF-4
significantly reduced the apoA-IV mRNA level (by 30%, P
0.05) in intestinal epithelial cells when compared with the control mice injected with the same amount of Ad-GFP. As an internal control, we analyzed the expression of the oxysterol receptor
[liver X receptor (LXR)
] gene and sterol response element-binding protein (SREBP)-1c, two genes that are not affected by the hepatic knockout of the HNF-4
gene (37). LXR
and SREBP-1c mRNA levels did not vary significantly (Fig. 2C
). Altogether, these experiments demonstrate that HNF-4 controls the expression of the apoA-IV gene in vivo and ex vivo in enterocytes.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 2. In Vivo Effect of a HNF-4 Dominant-Negative Form on Intestinal apoA-IV mRNA Levels
A, GFP visualization 5 d after intraduodenal injection of recombinant adenovirus (Ad-GFP) or PBS (control). Cr, Crypts; Vi, Villi. The arrowheads and the arrows point to positive epithelial cells from, respectively, the crypt and the villus of the same structural unit. Bar, 75 µm. B, Quantification of the apoA-IV mRNA levels in intestine after intraduodenal injections of PBS, recombinant adenovirus expressing the HNF-4 dominant-negative form (Ad-DN-HNF-4 ) or Ad-GFP. The inset displays the detection of DN-HNF-4 mRNA in injected mice. C, Quantification of LXR and SREBP-1c mRNA levels in intestine after intraduodenal injections of Ad-DN-HNF-4 or Ad-GFP. a, P 0.05 with respect to the infection with Ad-GFP.
|
|
Functional Characterization of HNF-4
and
Binding to the Proximal and Distal Regions of the apoA-IV Promoter
We have previously shown that the distal region (700/310) of the human apoA-IV promoter contains an HRE (AIV-E, Fig. 3A
) that binds the HNF-4
and
isoforms (16). A second HRE (AIV-C, Fig. 3A
) is present in the proximal region of the apoA-IV promoter (13). Comparison of the sequences of the human and mouse distal and proximal apo A-IV promoter regions (nucleotide 700 to +10, GenBank accession nos. gi 178756 and gi 192006), using the basic local alignment and search tool sequence alignment program, showed that the distal HRE (AIV-E) and the proximal HRE (AIV-C) were conserved in the two species (Fig. 3B
).

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 3. Schematic Representation of the apoC-III/A-IV Intergenic Region
A, Physical organization of the apoC-III/apoA-IV gene control regions. Arrows indicate the 5' to 3' orientation of the apoC-III and apoA-IV genes. The nucleotide positions are indicated from 5' to 3' relative to their respective transcription initiation start sites. B, Sequence homologies between human and mouse proximal (A-IV C) and distal (A-IV E) apoA-IV HREs. Nucleotides that represent the HRE in elements E and C are in bold. Lines indicate nucleotide homology and dashed lines, purine or pyrimidine homology.
|
|
To compare the affinity of the two HNF-4 isoforms for the apoA-IV HREs, we expressed these two isoforms in COS-7 cells and analyzed the complexes assembled on each sequence. We observed a single and specific complex with each HNF-4 isoform (Fig. 4A
) with both probes. The HNF-4
/DNA complex was completely supershifted with its corresponding antibody (Fig. 4A
, lanes 2 and 8), but not with the anti-HNF-4
antibody (Fig. 4A
, lanes 3 and 9). Likewise, the HNF-4
/DNA complex (Fig. 4A
, lanes 6 and 12), but not the HNF-4
/DNA complex (Fig. 4A
, lanes 5 and 11), was completely supershifted with the anti-HNF-4
antibody. We used whole cell extracts from these transfected COS-7 cells to determine the relative affinities of each HNF-4 isoform for the distal (probe E) and proximal (probe C) HREs of the apoA-IV promoter. For these studies, the radiolabeled HRE was competed out with increasing amounts of homologous nonradioactive competitor (Fig. 4
, B and C) or with the other HRE in heterologous competition (Fig. 4D
). The relative affinities of HNF-4
and
for the HREs were estimated from the slopes of the linear relationships (Fig. 4
, BD). HNF-4
and HNF-4
displayed the same affinity for the distal HRE (AIV-E) (Fig. 4B
) and for the proximal HRE (AIV-C) (Fig. 4C
). Heterologous competitions revealed that HNF-4
(Fig. 4D
) and HNF-4
(published as supplemental data Fig. S1 on The Endocrine Societys Journals Online web site at http://mend.endojournals.org) display a better binding to the distal HRE (AIV-E) than to the proximal HRE (AIV-C) (1.5- and 4-fold, respectively). Taken together, these results indicated that HNF-4
and HNF-4
bind slightly better to the distal than to the proximal HRE and that the two isoforms display comparable affinities for each HRE.

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 4. In Vitro Characterization of HNF-4 and Binding to apoA-IV Proximal (141/128) and Distal (377/357) HREs
A, EMSA with whole cell extracts from COS-7 cells transfected with HNF-4 (lanes 13 and 79) or HNF-4 (lanes 46 and 1012) expressing vectors. B, and C, Relative affinities of HNF-4 (filled diamond) and (open square) for distal and proximal HREs are determined by EMSAs, with probe E and with probe C, respectively. D, The relative affinity of HNF-4 for probe C and E determined by EMSAs. Increasing amounts of cold competitor (AIV-E in B, AIV-C in C, AIV-C filled squares and AIV-E open circles in D) were mixed with a constant amount of the radioactive probe in B, C, D. The fraction of bound probe (bound/bound+free) was estimated by scintillation counting of the radioactive bands. Insets show corresponding autoradiograms of probe-protein complexes. These experiments were done three times and a representative experiment is shown. E, Transactivation of the apoA-IV promoter by transient cotransfections of the eC3A4 reporter and the vector expressing each HNF-4 isoform in COS-7 or CaCo-2/TC7 cells.
|
|
The functional significance of the HNF-4 isoforms binding to the distal and proximal HREs of the apoA-IV promoter was then analyzed by transient expression assays of COS-7 or Caco-2/TC7 cells transfected with a CAT reporter construction containing the human (700/+10) apoA-IV promoter linked to the human (520/890) apoC-III enhancer (eC3A4, Fig. 3A
). HNF-4
and
both transactivated the eC3A4 construction in COS-7 cells in a similar dose-dependent manner (Fig. 4E
). Moreover, cotransfection with both isoforms led to a similar dose-dependent transactivation (Fig. 4E
). In Caco-2 cells, overexpression of the two isoforms led to similar transactivation levels (Fig. 4E
), although they were lower than the levels reached in COS-7 cells (1.8-fold compared with 10- to 13-fold). This difference results from the high level of endogenous HNF-4 in Caco-2 cells. We concluded from these transient transfections that the two HNF-4 isoforms activated the apoA-IV promoter at comparable levels.
Ex Vivo Analysis of the Respective Roles of the Two HREs in the Expression of the apoA-IV Gene in Enterocytes
The involvement of the proximal HRE (AIV-C, Fig. 3A
) in the apoA-IV gene expression in enterocytes was studied in cells transfected with the CAT reporter gene under the control of the human 700/+10 apoA-IV promoter linked to the 890/520 apoC-III enhancer (eC3A4). We introduced mutations (described in Fig. 5A
) in the distal HRE (AIV-E), in the proximal HRE (AIV-C) or in both elements (eC3A4Em, eC3A4Cm, and eC3A4EmCm; see Fig. 5C
).

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 5. Functional Characterization of the Proximal (141/128) and Distal (377/357) HREs
A, Mutations in the proximal (141/128, AIV-C) and distal (377/357, A-IV-E) HREs. Mutated nucleotides are underlined. Em, mutated E; Cm, mutated C. B, Competition EMSA performed with whole cell extract from COS-7 cells transfected with HNF-4 . The mutated oligonucleotide was used in 100-fold excess relative to the P32-labeled probe. C, Caco-2/TC7 cells were stably transfected with the CAT reporter gene under the control of various constructs of the apoA-IV promoter. The Caco-2/TC7 WT represent the CAT activity of the nontransfected parental cell line. The CAT activities were estimated on fully differentiated cells (see Materials and Methods). Asterisks, Mutated HREs.
|
|
These mutations completely suppressed HNF-4 binding to the proximal HRE (AIV-C), as previously described in Ktistaki et al. (Fig. 3
in Ref.13), and to the distal HRE (AIV-E), as shown in Fig. 5B
. With the E probe, the single and specific complex observed with HNF-4
is not competed out with a 100-fold excess of mutated nonradiolabeled competitor (Fig. 5B
, lane 3).
Because 1) Caco-2/TC7 cells can only be transfected when they are dividing and 2) the apoA-IV gene is only expressed in postconfluent and well-differentiated enterocytic Caco-2/TC7 cells, we generated permanent Caco-2/TC7 cell lines stably expressing the different constructs. Figure 5C
shows that in the stable cell lines CAT activity decreased dramatically when a single site was altered. The activities of the mutated promoters remained significantly above background levels. From these data, we conclude that in enterocytic cells the full activity of the apoA-IV promoter requires the integrity of both the distal and the proximal HREs.
In Vivo Analysis of the Respective Roles of the Two HREs in the Expression of the apoA-IV Gene in Enterocytes
We investigated the respective binding pattern of the two HREs using nuclear extracts prepared from villus or crypt cells. Both nuclear extracts produced a single slowly migrating band with either the proximal HRE (AIV-C) (lanes 1 and 5, Fig. 6A
) or the distal HRE (AIV-E) probe (lanes 9 and 13, Fig. 6A
). In each case, HNF-4
-directed antibodies produced a supershift (Fig. 6A
, lanes 2, 6, 10, and 14), but a complex remained at the initial position when using nuclear extracts purified from villi (Fig. 6A
, lanes 2 and 10). We have previously shown for the distal HRE (AIV-E) that this complex could not be displaced by increasing amounts of anti-HNF-4
. Because different nuclear receptors can bind a HRE, we tested various antibodies and demonstrated that HNF-4
was present in the complex with the distal HRE (AIV-E), but not apolipoprotein A-I regulatory protein-1, v-erbA-related protein 3, retinoic acid receptor
, or retinoid X receptor
(16). However, their migration patterns in band-shift assays are different from those of HNF-4
. Here, the presence of a supershifted complex with an antibody directed against HNF-4
clearly revealed that this isoform was present in the villi nuclear extracts and could bind to AIV-C and to AIV-E (Fig. 6A
, lanes 3 and 11). Furthermore, when anti-HNF-4
and anti-HNF-4
antibodies were added together, the complexes formed with villus nuclear extracts were supershifted (Fig. 6A
, lanes 4 and 12). Conversely, the complex formed with crypt nuclear extracts was almost completely supershifted by the anti-HNF-4
antibody (Fig. 6A
, lanes 6 and 14), but not by the anti-HNF-4
antibody (Fig. 6A
, lanes 7 and 15). This is consistent with the fact that HNF-4
is only expressed in villi (16). The slight supershift observed with the anti-HNF-4
antibody resulted from a contamination of the crypt cell fraction with the more abundant villus cells (supplemental data Fig. S2). Altogether, these results demonstrate that both proximal (AIV-C) and distal (AIV-E) HREs of the apoA-IV promoter display the same binding profile of villus and crypt nuclear extracts.

View larger version (70K):
[in this window]
[in a new window]
|
Fig. 6. In Vivo Effect of Mutations in Distal and/or Proximal HREs of the apoA-IV Promoter
A, EMSA performed with the proximal (probe C) or distal (probe E) HREs and with nuclear extracts from mice villi (lanes 14 and 912) or mice crypts (lanes 58 and 1316). The arrow points to the DNA-HNF4 complexes and the bracket to the super-shifted complexes. B, Distribution of CAT activity along the small intestine in five transgenic mouse lines expressing the CAT constructions shown under each histogram. CAT activity of each intestinal segment, proximal (Prox), middle (Mid), or distal (Dist) was measured as described in Materials and Methods and is expressed as the percentage of total CAT activity in the small intestine of the founder. CAT activities of the eC3A4, eC3pA4 and eC3A4Cm are expressed as the means of the three founders. The eC3A4 profile is shown for reference and has been published (16 ). a, P 0.05, b, P 0.01, c, P 0.001 with respect to the CAT activity in the proximal part. C, Immunohistological localization of CAT on jejunal sections from nontransgenic mice (panel a), and transgenic mice expressing the CAT reporter gene under the control of various constructs of the apoA-IV promoter, eC3A4 (panel b), eC3A4Cm (panel c), eC3A4Em (panel d), and eC3pA4 (panel e). Bar, 75 µm. Insets of villi (Vi) and crypts (Cr) are 1.5-fold magnifications of the dashed and plain squares, respectively. The immunohistochemistry reactions were performed on jejunal sections from transgenic mice with one to five copies of the CAT gene. D, RT-PCR on mRNA samples from crypts (Cr) and villi (Vi) obtained by laser microdissection of jejunal sections from transgenic mice. 0, Control of the RT-PCR (i.e. a reverse transcriptase reaction without RNA).
|
|
The intestinal apoA-IV expression follows a cephalo-caudal gradient and the gene is not expressed in crypts. To assess in vivo the functional role of the apoA-IV HREs, we generated transgenic mice expressing the constructions described above. The expression of the reporter gene was determined along the cephalo-caudal and crypt-villus axes for each mutant (Fig. 6
, B and C, respectively). The CAT activity was determined along the small intestine for each transgenic mouse line (supplemental data Figs. S3 and S4). A decreasing cephalo-caudal gradient of CAT activity was observed when the reporter gene was controlled by eC3A4, eC3A4Cm or eC3A4Em promoters, i.e. constructions that retained one functional HRE in the human apoA-IV promoter (Fig. 6B
). However, the gradient was suppressed in mice expressing the eC3A4CmEm-CAT transgene in which both HREs of the apoA-IV promoter are mutated (Fig. 6B
). To further assess the role of the proximal HRE (AIV-C), we generated additional transgenic mice expressing the CAT transgene under the control of the (520/890) apoC-III enhancer fused to the (310/+10) proximal apoA-IV promoter, named eC3p4. As already observed in mice expressing the eC3A4Em or eC3A4Cm construction, we measured a decreasing gradient of CAT activity along the cephalo-caudal axis in these mice (Fig. 6B
). Thus, in vivo, the presence of a single HRE within the apoA-IV promoter is sufficient to maintain the cephalo-caudal gradient of expression.
CAT expression was then analyzed by immunohistochemistry along the crypt-villus axis of the transgenic mice (Fig. 6C
). The specificity of the signal was verified using jejunum sections from non transgenic mice (Fig. 6C
-a) and from eC3A4 transgenic mice as controls (Fig. 6C
-b). In the latter, the transgene expression was restricted to villi, as previously shown by in situ hybridization (16). In transgenic mice in which the proximal HRE (AIV-C) (Fig. 6C
-c) or the distal HRE (AIV-E) (Fig. 6C
-d) was mutated, the CAT protein was detected in the villus epithelium (comparing the intensity of the signal in Fig. 6C
, villus insets) and accumulated in crypts (comparing the fluorescence signals in Fig. 6C
, crypt insets). Moreover, immunochemical analysis studies revealed that the CAT reporter gene was expressed in crypt and villus cells of eC3pA4 transgenic mice (Fig. 6C
-e).
The CAT reporter gene expression patterns were confirmed by RT-PCR analysis of mRNA extracted from villus or crypt cells, isolated by laser microdissection of intestinal sections from these transgenic mice (Fig. 6D
). The same mRNA samples were used to analyze endogenous apoA-IV expression by RT-PCR. The lack of apoA-IV signal from transgenic mice crypts and, to a lesser extent, from the control mice crypts when compared with the signals from villi, shows that these fractions were almost free of villus mRNA. As expected, CAT expression was only detected in villi of the eC3A4 transgenic mice. On the other hand, CAT expression was detected in crypts and villi from the eC3A4Cm, eC3A4Em, and eC3A4CmEm transgenic mice. 18S RNA was present at the same levels in crypt and villus fractions from all mice (Fig. 6D
). Thus, in vivo, mutation of a single HRE lowers the apoA-IV promoter activity in enterocytes. More strikingly, this allows the expression of the reporter gene in crypts, abolishing the spatial restriction of the apoA-IV gene expression to the villi. Altogether, these results suggest that in transgenic mice, both HREs of the human apo A-IV promoter are necessary to restrict gene expression to villus epithelial cells.
 |
DISCUSSION
|
---|
This study demonstrates for the first time that HNF-4 controls apoA-IV gene expression in vivo in intestinal epithelial cells. HNF-4
and HNF-4
isoforms bind similarly to the distal and proximal HREs of the human apoA-IV promoter. Both HREs are necessary to restrict transcription of a reporter gene to villus epithelial cells, whereas the expression pattern that decreases along the cephalo-caudal axis only requires one or the other HRE.
Using an adenovirus coding for a dominant-negative form of HNF-4
, we reduced the expression of apoA-IV in enterocytic Caco-2 cells in a time- and dose-dependent manner. This dominant-negative form has already been used to impair the effect of glucose on the hepatic expression of apoA-II gene, another target of HNF-4
(41). The dominant-negative HNF-4
lacks the C-terminal transactivating domain but is still able to dimerize and bind to DNA (38). Considering the overall similarities and identities in the amino acid sequences of HNF-4
and
, we might expect that the dominant-negative HNF-4 could also dimerize with HNF-4
. We found no experimental evidence for such heterodimerization despite many attempts and different approaches. Two helical domains, H9 and H10, play an essential role for the dimerization of HNF-4 polypeptides (39). The HNF-4
sequence is well conserved among human, rat, and mouse; this is also the case for HNF-4
between human and mouse (the rat sequence has not been reported). It is noteworthy that the sequence of helix 10 is fully conserved between the
and
isoforms, in human and mouse, whereas that of helix 9 diverges (six differences out of 21 residues). We thus believe that inhibition results from a competitive binding to the different HREs. The binding of another nuclear receptor is unlikely because, in intestinal nuclear extracts, only HNF-4
and
bind to the HREs of the apoA-IV promoter (see also Ref.16).
We infected the small intestine epithelium of mice with this adenovirus and observed a significant decrease in the apoA-IV gene expression. Differences in adenovirus transduction efficiency ex vivo and in vivo, as well as the rapid self-renewal of the intestinal epithelium, most likely account for the smaller decrease in apoA-IV expression observed in vivo as compared with that observed in cell cultures. Furthermore, the dominant-negative HNF-4
also affects the expression of genes involved in the lipid metabolism of the intestine, as has already been demonstrated for the liver with a conditional knockout of Hnf-4
(37). These results show that recombinant adenoviruses can be used to investigate transcriptional regulation in the intestinal epithelium. In the liver, HNF-4
plays a central role in hepatocyte differentiation and in the maintenance of differentiated hepatocytes by regulating the expression of genes involved in the control of lipid metabolism (35, 37). Our data demonstrate that the HNF-4 transcription factor family is also a major regulator of cell-specific gene expression in the intestine and could play a central role in digestive epithelium development, enterocyte differentiation, and the maintenance of enterocyte functions, and particularly, that of lipid metabolism.
The second question addressed by this study was to determine the respective roles of the different HREs in the control of apoA-IV gene expression along the intestinal crypt-villus and cephalo-caudal axes. HREs, the regulatory sequences bound by HNF-4 transcription factors, have been shown to play a major role in the expression of the apoA-I/C-III/A-IV gene cluster. The intestinal expression of these genes requires the HRE located in the apoC-III enhancer (7, 8, 42, 43). In this work, we demonstrate that the physiological gradient of apoA-IV gene expression along the cephalo-caudal axis requires either one of the HREs located within the promoter (Fig. 7A
). Conversely, the two HREs of the apoA-IV promoter are necessary to restrict the expression to the villi (Fig. 7A
). Thus, distinct elements appear to be necessary to restrict apoA-IV expression to enterocytes and to direct transcription of the gene along the duodenum-ileal axis. This has also been reported for the rat intestinal fatty acid binding protein (FABP-I) gene. The FABP-I promoter (103/+28) is sufficient to direct transcription of this gene along the duodenum-colon axis. However, upstream sequences are needed to confine FABP-I expression to the differentiated enterocytes of the villus. In particular, a 20-bp element located between nucleotides 263 and 244 of the promoter prevents FABP-I expression in crypt cells (44, 45). This is also the case for the rat liver FABP and the sucrase-isomaltase genes (46, 47).
Because HNF-4
is expressed in villi and crypts, whereas HNF-4
is only expressed in villi (16), one could hypothesize that HNF-4
is the factor responsible for apoA-IV gene restriction to villi. In vitro, both isoforms display comparable affinities for the apoA-IV HREs and similar transactivating properties in COS-7 and CaCo-2 cells. Therefore, it is unlikely that the intestinal expression of the apoA-IV gene results solely from a competition between HNF-4
and HNF-4
.
The expression of apoA-IV along the crypt-villus axis relies on a two-step process: gene silencing in epithelial cells while they remain in crypts, followed by gene activation when these cells reach the villi as differentiated enterocytes. The presence of CAT activity in the crypts of transgenic mice with mutated apoA-IV promoters demonstrates that the integrity of the two HREs is required for gene silencing in crypts. Because only HNF-4
binds to these HREs in nuclear extracts from crypts, this suggests its involvement in the apoA-IV gene silencing. HNF-4
, like other nuclear receptors, interacts with coactivator and corepressor complexes, containing histone acetyltransferase or histone deacetylase (HDAC) activities (for review see Ref.48). Histone acetyltransferase and HDAC ultimately control the balance between chromatin decondensation, a transcriptionally permissive state, and chromatin condensation, a transcriptionally silent state (for review see Ref.49). In accordance with this, it has been shown recently that in the developing mouse intestine the Fabpi, Fabpl, and apoA-I genes, which are expressed in differentiated enterocytes, are specific targets for developmental modulation by class I HDAC (50). Thus, recruitment of endogenous class I HDAC by HNF-4 may participate in villus-restricted gene expression.
Recruitment of such coregulators by target promoters occurs mainly through direct physical interactions with the transactivation domains of nuclear receptors, with these interactions being modulated by the binding of the ligands. Wisely et al. (27) showed that HNF-4 constitutively binds fatty acids as structural ligands, raising the question of the mechanism of the switch from corepressor to coactivator complexes (30). Interestingly, it has been reported that the recruitment of different coregulators, and the subsequent promoter responses, differed between two HNF-4
isoforms (51, 52), and that this recruitment is mediated by the F domain of HNF-4
(53). This F domain exhibits only 32% identity between
and
isoforms (18).
As observed in the cellular model (Fig. 5C
) and in vivo (Fig. 6C
) mutation of a single HRE lowers the apo A-IV promoter activity in enterocytes. Thus, apoA-IV gene expression is not constitutive in enterocytes, but requires activating signals provided by interactions between HNF-4
or
dimers and enterocyte-specific coactivators. Conversely in crypts, where HNF-4
is not expressed, the repression of apoA-IV expression could be due to the recruitment of corepressors by the HNF-4
homodimers (Fig. 7B
). Our observations in cell lines and in transgenic mice strongly suggest that the activating or the inhibiting complexes should comprise at least three HNF-4 homodimers.
In conclusion, our results demonstrate that in the intestinal epithelium the specific pattern of apoA-IV gene expression along the crypt-villus axis is controlled by the binding of HNF-4 transcription factors to the two HREs located in the promoter and in the apoC-III enhancer. The switch observed in apoA-IV gene activity in epithelial cells from a silenced status in crypts to an active status in villi most likely requires the formation of specific transcriptional complexes recruiting corepressors in crypts and coactivators in villi to remodel chromatin. Such a mechanism, which has to be demonstrated, would confer a major role for HNF-4 in the onset and maintenance of differentiated functions in enterocytes, and particularly in lipid metabolism.
 |
MATERIALS AND METHODS
|
---|
Adenovirus
The recombinant adenovirus Ad-DN-HNF4
, expressing a truncated version of rat HNF-4
2 lacking the C-terminal residues 361465, was constructed from pCDNA1-HNF-4-Cd1b (38). pCDNA1-HNF-4-Cd1b was digested with HindIII and NotI; the Cd1b-containing fragment was then subcloned by blunt ligation into the EcoRI restriction site of the pTg-6600 vector. The recombinant adenovirus was then generated by in bacteria homologous recombination with the pKp1.3 vector. The production of infectious particles was performed by the GVPN (Gene Vector Production Network of Genethon, Evry, France). A recombinant adenovirus, Ad-GFP, containing a cytomegalovirus (CMV) promoter/GFP gene cassette was used as a control. The in vivo adenovirus infection experiments were performed as described in Cheng et al. (40) with modifications. The day before adenovirus injection, female B6CBA mice were fasted for 5 h and were orally loaded at 14 and 18 h with 0.3 ml of a mixture containing 100 mg of maternalized milk (Bledilait HA, Danone, France), 20% of acetylcysteine (wt/vol) (Mucomyst, Bristol-Myers Squibb, Paris, France) and ampicillin (60 mg/kg) in coloscopic liquid (Biopeg, Fresenius, Paris, France). The next day, they were anesthetized by ip injection of 2,2,2-tribromoethanol (0.25 mg/g, avertine, Sigma, St. Louis, MO). After a small abdominal incision on the right side, 100 µl of a mix containing glucagon (0.1 mg/kg, Sigma), dexamethasone (2 mg/kg, Dexadreson, Intervet, the Netherlands) and ranitidine (2 mg/kg, Raniplex, Fournier, France) in PBS was administered. Mice were divided into two groups (n = 3 in each group). The first group received an Ad-GFP injection and the second, an Ad-DN-HNF4
injection. Adenovirus (100 µl of 2.5 x 109 pfu/mouse in PBS) was injected into the intraduodenal lumen, the injection point was marked with a surgical thread, and the incision was closed. Mice were allowed to recover and given a regular chow diet. Eight days later, mice were euthanized and the small intestine (10 cm from the surgical mark) was removed, washed with PBS, and frozen in liquid nitrogen for further RNA analysis. The experiment was repeated five times. Animal care and the experimental procedures used in this study conform to the French guidelines for animal studies. For in vitro adenovirus infection experiments, Caco-2/TC7 cells were seeded in six-well plates with 8 x 104 cells per well and cultured as previously described (54). Ten days later, the cells were infected with Ad-DN-HNF4
or Ad-GFP (5 or 50 pfu/cell). Two, 3, or 5 d after infection, the medium was removed and cells were recovered for RNA analysis. Experiments were performed in triplicate and repeated three to five times.
Reverse Transcription (RT) Real-Time PCR
Total RNA from infected mouse intestine and Caco-2/TC7 cells was isolated with RNAplus reagent (qBiogene Illkirch, France) according to the manufacturers instructions. The RT reactions were performed with 1 µg of RNA in a 20-µl reaction. mRNA was quantified using the Light Cycler System according to the manufacturers procedures (Roche Molecular Biochemicals, Meylan, France). PCRs were performed with a 1:1000 final dilution of the RT product as previously described (41). The amount of human apoA-IV mRNA was quantified using hybridization probes designed by Genset (Proligo, Paris, France). The PCR conditions were one step of denaturation (8 min at 95 C) followed by 40 amplification cycles (each cycle consisted of 15 sec at 95 C, 10 sec at 58 C and 15 sec at 72 C). Mice apoA-IV, Cd1b, LXR
, and SREBP-1c and human apo B and L19 mRNA levels were quantified using the SYBR Green I dye. The PCR conditions were one step of denaturation (8 min at 95 C) followed by 40 amplification cycles (each cycle consisted of 10 sec at 95 C, 10 sec at 60 C and 10 sec at 72 C). The sequences of primers are shown in Table 1
. The quantification of 18S RNA (using Taqman probes from Applied Biosystems, Courtaboeuf, France) was used as an internal control. Results were expressed as the ratio between the mRNA of interest and 18S RNA.
Nuclear Extracts from Mouse Intestinal Epithelial Cells
The epithelium was isolated (55), and villi and crypt cells were isolated by shaking intestine fragments in a chelating buffer (56), as previously described (16). Nuclear extracts from intestinal epithelial cells were then prepared according to Shapiro et al. (57).
Preparation of Whole-Cell Extracts from COS-Transfected Cells
The vector encoding rat HNF-4
2 (pMT2-HNF-4
) is as previously described (11). Mouse HNF-4
cDNA was subcloned into the EcoRI site of pMT2 vector (11) after amplification from pCMV-HNF-4
(18). COS-7 cells were transfected with these two expression vectors by the calcium phosphate coprecipitation method. Whole-cell extracts were prepared as previously described for use in gel retardation assays (58).
EMSAs
The AIV-E and AIV-C double-stranded oligonucleotides used as probes or competitors for EMSAs are described in Fig. 1B
. EMSAs were performed as previously described (58) with 2 µl of COS-7 whole cell extract or with 2 µg of nuclear extract from villus or crypt epithelial cells. For competition assays and affinity estimations, the unlabeled double-stranded oligonucleotide and the radioactive probe were added simultaneously. Supershift experiments were performed with antibodies directed against HNF-4
(C-19X) and HNF-4
(C-18X), according to the manufacturers instructions (Santa Cruz Biotechnology, Inc., Santa Cruz, CA).
CAT Gene Reporter Plasmids
The details concerning construction of the plasmids eC3pA4, eC3A4Cm, eC3A4Em, and eC3A4CmEm are presented in the supplemental data Fig. S5; eC3A4 has already been described (15). We verified that the mutations were present in the different constructions by sequencing. The mutations introduced in the HREs in elements E and C are indicated in Fig. 3B
.
Transient Cell Tranfections
Caco-2/TC7 and COS-7 cells were seeded into six-well plates with 2 x 105 and 105 cells per well, respectively, and were allowed to adhere overnight. Cells were transfected by incubation for 24 h with CAT expressing vector (2.5 µg), HNF-4 expressing vectors (0.5 µg or variable amounts as indicated in the figures for COS-7 cells), and ß-galactosidase expressing vector (0.5 µg) in opti-MEM supplemented with 8 µg of lipofectin reagent (Invitrogen Life Technologies, Carlsbad, CA), according to the manufacturers instructions. After transfection, the medium was replaced with supplemented DMEM-glutamax (25 mM glucose, 20% fetal bovine serum), and the cells were incubated for a further 24 h. Experiments were performed in triplicate and repeated three to five times.
Stably Transfected Cells
Caco-2/TC7 cells were cotransfected using the calcium phosphate coprecipitation method with different plasmids expressing the CAT reporter gene as indicated in Fig. 4
and a selection plasmid coding for the neomycin resistance gene. The whole populations of stably transfected cell lines were selected with G418 (400 µg/ml) for 3 wk as previously described (54). To assay the CAT activity in the different lines, the stably transfected cells were grown on a semipermeable insert with an asymmetrical distribution of medium between the apical side (with 20% fetal calf serum) and the basal side (without fetal calf serum) for 21 d to allow the complete epithelium organization of Caco-2/TC7 cells, as previously described (59). Experiments were performed in triplicate and repeated three times.
Generation and Characterization of Transgenic Mice
Transgenic mice were obtained as previously described (15, 16). Briefly, the transgenes were excised from plasmids and microinjected into fertilized eggs from C57BL/6J x CBA/J females. DNA from pups tails was analyzed by PCR for the presence of the CAT gene. The DNA from positive mice was then further analyzed by Southern blot to estimate the copy number of the transgene (supplemental data Fig. S6). Three founders of the eC3A4 Cm-CAT transgene were obtained with 2, 1, and 2030 copies (per genome), respectively. One founder each of the eC3A4 Em-CAT transgene and of the eC3A4 CmEm-CAT transgene were obtained with 1 and 1020 copies, respectively. Two founders of the eC3pA4-CAT transgene with one and two to five copies, respectively, were identified. The transgenes are integrated at a single locus in each line.
CAT Assays
Individual tissues were homogenized as previously described (15) and transiently or stably transfected cells were recovered. The soluble protein concentration was determined with the Bio-Rad (Hercules, CA) protein assay. CAT activities were measured using a liquid phase assay, as previously described (58). CAT activity is expressed as percentage of acetylation per minute per milligram of protein, after subtracting the background for each tissue from control mice, which do not express the CAT gene. In transient transfections, ß-galactosidase activity was determined to normalize the variability in transfection efficiency (58). In stably transfected cells, the CAT activity was normalized with the protein concentration.
Immunohistochemistry
Sections of small intestine from mice were fixed by incubation for 10 min in 4% paraformaldehyde in PBS and washed six times, for 5 min each, in PBS. The sections were incubated for 30 min in blocking solution (2% BSA, 0.2% Tween, 100 mM glycine in PBS) and then for 1 h at room temperature with anti-CAT-digoxigenin antibody [dilution: 1/50; Roche Molecular Biochemicals (Indianapolis, IN); no. 1 465 066]. The sections were washed six times with PBS, then incubated with blocking solution, followed by the secondary antibody, anti-digoxigenin-rhodamin (dilution:1/20; Roche; no. 1 207 750). After several washes, the samples were mounted with antifading mixture Fluoprep (Biomerieux, Marcy lEtoile, France). Images were acquired with a Zeiss LSM-510 laser-scanning confocal microscope (Carl Zeiss, Oberkochen, Germany) equipped with Zeiss Axiovert 100M (plan neofluar 16x NA 0.5 oil immersion objective).
Laser Microdissection and mRNA Detection
Laser microdissections of jejunal sections (7 µm) were performed, with an AS LMD Leica system used to collect crypt and villus cells, as described in Sauvaget et al. (16). RNA extractions and RT reactions were performed as previously described (16). The cDNAs were analyzed by real-time PCR amplification after 1/10 dilution. Detection of mouse apoA-IV mRNA and 18S RNA is as described in the RT real-time PCR section. The CAT mRNA was detected using the SYBR Green I dye. The PCR conditions were one step of denaturation (8 min at 95 C) followed by 40 amplification cycles (10 sec at 95 C, 10 sec at 60 C, and 10 sec at 72 C), with CAT primers described in Table 1
. PCR products were visualized by agarose gel electrophoresis with ethidium bromide staining.
Statistical Analysis
Results were expressed as means ± SEM. The statistical significance of differences was determined by the unpaired Students t test using Excel software.
 |
ACKNOWLEDGMENTS
|
---|
We thank M. Hadzopoulou-Cladaras (Department of Biology, Section of Genetics, Developmental and Molecular Biology, Aristotelian University of Thessaloniki, Thessaloniki, Greece) for providing the CD1b expression vector, S. Taraviras and E. F. Greiner (from G. Schütz laboratory, Division of Molecular Biology of the Cell 1, German Cancer Research Center, Heidelberg, Germany) for providing the pCMV-HNF4
expression vector, V. Becette (Department of Anatomo-pathology, Centre René Huguenin, Saint-Cloud, France) for access to the laser microdissection system, and L. Garcia (Généthon, Evry, France) for providing the GFP-expressing adenovirus. We thank the Production and Control Department of Genethon, which is supported by the Association Française contre les Myopathies (AFM), for production of the adenoviral stocks in the context of the GVPN network (http://www.gvpn.org). We also thank M. Séau and C. Lasne (Laboratoire de Transgenèse, IFR 58, Institut des Cordeliers, Paris, France) for technical assistance in the generation of transgenic mice, A. Bobard [by Institut National de la Santé et de la Recherche Médicale (INSERM) Unité 465, Institut des Cordeliers, Paris, France] for PCRs of SREBP-1c and LXR
and J-M. Lacorte and R. Vidal (INSERM Unité 505, Institut des Cordeliers, Paris, France) for stably transfected Caco-2/TC7 lines. The confocal microscopy analysis was performed thanks to the cellular imaging platform IFR58 (Institut des Cordeliers, Paris, France). We thank Rachel Carol (Ecole Pratique des Hautes Etudes, Paris, France) for editing and rewriting the manuscript.
 |
FOOTNOTES
|
---|
This work was supported by INSERM and Pierre & Marie Curie University (Paris VI, Paris, France). A.A. is a recipient of a doctoral fellowship from the Ministère de lEnseignement Supérieur et de la Recherche.
First Published Online May 31, 2005
Abbreviations: Ad-GFP, Adenovirus expressing GFP; apo, Apolipoprotein; CAT, chloramphenicol acetyltransferase; CMV, cytomegalovirus; FABP, fatty acid binding protein; GFP, green fluorescent protein; GVPN, Gene Vector Production Network; HDAC, histone deacetylase; HNF, hepatic nuclear factor; HRE, hormone-responsive element; LXR, liver X receptor; RT, reverse transcription; SREBP, sterol response element-binding protein.
Received for publication November 17, 2004.
Accepted for publication May 18, 2005.
 |
REFERENCES
|
---|
- Stan S, Delvin E, Lambert M, Seidman E, Levy E 2003 Apo A-IV: an update on regulation and physiologic functions. Biochim Biophys Acta 1631:177287[Medline]
- Liu M, Doi T, Tso P 2003 Regulation of intestinal and hypothalamic apolipoprotein A-IV. Exp Biol Med (Maywood) 228:11811910[Abstract/Free Full Text]
- Ezeh B, Haiman M, Alber HF, Kunz B, Paulweber B, Lingenhel A, Kraft HG, Weidinger F, Pachinger O, Dieplinger H, Kronenberg F 2003 Plasma distribution of apoA-IV in patients with coronary artery disease and healthy controls. J Lipid Res 44:15231529[Abstract/Free Full Text]
- Kronenberg F, Stuhlinger M, Trenkwalder E, Geethanjali FS, Pachinger O, von Eckardstein A, Dieplinger H 2000 Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease. J Am Coll Cardiol 36:751757[Abstract/Free Full Text]
- Zannis VI, Cole FS, Jackson CL, Kurnit CL, Karathanasis SK 1985 Distribution of apolipoprotein A-I, C-II, C-III, and E mRNA in fetal human tissues. Time-dependent induction of apolipoprotein E mRNA by cultures of human monocyte-macrophages. Biochemistry 24:44504455[CrossRef][Medline]
- Elshourbagy NA, Boguski MS, Liao WSL, Jefferson LS, Gordon JI, Taylor JM 1985 Expression of rat apolipoprotein A-IV and A-I genes: mRNA induction during development and in response to glucocorticoids and insulin. Proc Natl Acad Sci USA 82:82428246[Abstract/Free Full Text]
- Kan H-Y, Georgopoulos S, Zannis VI 2000 A hormone response element in the human apolipoprotein CIII (ApoCIII) enhancer is essential for intestinal expression of the ApoA-I and ApoCIII genes and contributes to the hepatic expression of the two linked genes in transgenic mice. J Biol Chem 275:3042330431[Abstract/Free Full Text]
- Bisaha JG, Simon TC, Gordon JI, Breslow JL 1995 Characterization of an enhancer element in the human apolipoprotein C-III gene that regulates human apolipoprotein A-I gene expression in the intestinal epithelium. J Biol Chem 270:1997919988[Abstract/Free Full Text]
- Ginsburg GS, Ozer J, Karathanasis SK 1995 Intestinal apolipoprotein AI gene transcription is regulated by multiple distinct DNA elements and is synergistically activated by the orphan nuclear receptor, hepatocyte nuclear factor 4. J Clin Invest 96:528538[Medline]
- Kardassis D, Tzameli I, Hadzopoulou-Cladaras M, Talianidis I, Zannis VI 1997 Distal apolipoprotein C-III regulatory elements F to J act as a general modular enhancer for proximal promoters that contain hormone response elements. Synergism between hepatic nuclear factor-4 molecules bound to the proximal promoter and distal enhancer sites. Arterioscler Thromb Vasc Biol 17:222232[Abstract/Free Full Text]
- Ladias JA, Hadzopoulou-Cladaras M, Kardassis D, Cardot P, Cheng J, Zannis VI, Cladaras C 1992 Transcriptional regulation of human apolipoprotein genes ApoB, ApoCIII, and ApoAII by members of the steroid hormone receptor superfamily HNF-4, ARP-1, EAR-2, and EAR-3. J Biol Chem 267:1584915860[Abstract/Free Full Text]
- Mietus-Snyder M, Sladek FM, Ginsburg GS, Kuo CF, Ladias JAA, Darnell Jr JE, Karathanasis SK 1992 Antagonism between apolipoprotein AI regulatory protein 1, Ear3/COUP-TF, and hepatocyte nuclear factor 4 modulates apolipoprotein CIII gene expression in liver and intestinal cells. Mol Cell Biol 12:17081718[Abstract]
- Ktistaki E, Lacorte J-M, Katrakili N, Zannis VI, Talianidis I 1994 Transcriptional regulation of the apolipoprotein A-IV gene involves synergism between a proximal orphan receptor response element and a distant enhancer located in the upstream promoter region of the apolipoprotein C-III gene. Nucleic Acids Res 22:46894696[Abstract]
- Talianidis I, Tambakaki A, Toursounova J, Zannis VI 1995 Complex interactions between SP1 bound to multiple distal regulatory sites and HNF-4 bound to the proximal promoter lead to transcriptional activation of liver-specific human APOCIII gene. Biochemistry 34:1029810309[CrossRef][Medline]
- Le Beyec J, Chauffeton V, Kan H-Y, Janvier P-L, Cywiner-Golenzer C, Chatelet F-P, Kalopissis AD, Zannis VI, Chambaz J, M Pinçon-Raymond, Cardot P 1999 The 700/310 fragment of the apolipoprotein A-IV gene combined with the 890/500 apolipoprotein C-III enhancer is sufficient to direct a pattern of gene expression similar to that for the endogenous apolipoprotein A-IV gene. J Biol Chem 274:49544961[Abstract/Free Full Text]
- Sauvaget D, Chauffeton V, Citadelle D, Chatelet F-P, Cywiner-Golenzer C, Chambaz J, Pinçon-Raymond M, Cardot P, Le Beyec J, Ribeiro A 2002 Restriction of apolipoprotein A-IV gene expression to the intestine villus depends on a hormone-responsive element and parallels differential expression of the hepatic nuclear factor 4
and
isoforms. J Biol Chem 277:3454034548[Abstract/Free Full Text]
- Drewes T, Senkel S, Holewa B, Ryffel GU 1996 Human hepatocyte nuclear factor 4 isoforms are encoded by distinct and differentially expressed genes. Mol Cell Biol 16:925931[Abstract]
- Taraviras S, Mantamadiotis T, Dong-Si T, Mincheva A, Lichter P, Drewes T, Ryffel GU, Monaghan AP, Schutz G 2000 Primary structure, chromosomal mapping, expression and transcriptional activity of murine hepatocyte nuclear factor 4
. Biochim Biophys Acta 1490:2132[Medline]
- Chawengsaksophak K, James R, Hammond VE, Kontgen F, Beck F 1997 Homeosis and intestinal tumours in Cdx2 mutant mice. Nature 386:8487[CrossRef][Medline]
- James R, Erler T, Kazenwadel J 1994 Structure of the murine homeobox gene cdx-2. Expression in embryonic and adult intestinal epithelium. J Biol Chem 269:1522915237[Abstract/Free Full Text]
- Subramanian V, Meyer BI, Gruss P 1995 Disruption of the murine homeobox gene Cdx1 affects axial skeletal identities by altering the mesodermal expression domains of Hox genes. Cell 83:641653[CrossRef][Medline]
- Gao X, Sedgwick T, Shi YB, Evans T 1998 Distinct functions are implicated for the GATA-4, -5, and -6 transcription factors in the regulation of intestine epithelial cell differentiation. Mol Cell Biol 18:29012911[Abstract/Free Full Text]
- Laverriere AC, MacNeill C, Mueller C, Poelmann RE, Burch JB, Evans T 1994 GATA-4/5/6, a subfamily of three transcription factors transcribed in developing heart and gut. J Biol Chem 269:2317723184[Abstract/Free Full Text]
- Aranda A, Pascual A 2001 Nuclear hormone receptors and gene expression. Physiol Rev 81:12691304[Abstract/Free Full Text]
- Sladek FM, Zhong WM, Lai E, Darnell Jr JE 1990 Liver-enriched transcription factor HNF-4 is a novel member of the steroid hormone receptor superfamily. Genes Dev 4:23532365[Abstract]
- Dhe-Paganon S, Duda K, Iwamoto M, Chi YI, Shoelson SE 2002 Crystal structure of the HNF4
ligand binding domain in complex with endogenous fatty acid ligand. J Biol Chem 277:3797337976[Abstract/Free Full Text]
- Wisely GB, Miller AB, Davis RG, Thornquest Jr AD, Johnson R, Spitzer T, Sefler A, Shearer B, Moore JT, Miller AB, Willson TM, Williams SP 2002 Hepatocyte nuclear factor 4 is a transcription factor that constitutively binds fatty acids. Structure 10:12251234[CrossRef][Medline]
- Duda K, Chi Y-I, Shoelson SE 2004 Structural basis for HNF-4
activation by ligand and coactivator binding. J Biol Chem 279:2331123316[Abstract/Free Full Text]
- Petrescu AD, Hertz R, Bar-Tana J, Schroeder F, Kier AB 2002 Ligand specificity and conformational dependence of the hepatic nuclear factor-4
(HNF-4
). J Biol Chem 277:2398823999[Abstract/Free Full Text]
- Sladek FM 2002 Desperately seeking... something. Mol Cell 10:219221[CrossRef][Medline]
- Zhong W, Sladek FM, Darnell Jr JE 1993 The expression pattern of a Drosophila homolog to the mouse transcription factor HNF-4 suggests a determinative role in gut formation. EMBO J 12:537544[Abstract]
- Chen WS, Manova K, Weinstein DC, Duncan SA, Plump AS, Prezioso VR, Bachvarova RF, Darnell Jr JE 1994 Disruption of the HNF-4 gene, expressed in visceral endoderm, leads to cell death in embryonic ectoderm and impaired gastrulation of mouse embryos. Genes Dev 8:24662477[Abstract]
- Duncan SA, Manova K, Chen WS, Hoodless P, Weinstein DC, Bachvarova RF, Darnell Jr JE 1994 Expression of transcription factor HNF-4 in the extraembryonic endoderm, gut, and nephrogenic tissue of the developing mouse embryo: HNF-4 is a marker for primary endoderm in the implanting blastocyst. Proc Natl Acad Sci USA 91:75987602[Abstract/Free Full Text]
- Duncan SA, Nagy A, Chan W 1997 Murine gastrulation requires HNF-4 regulated gene expression in the visceral endoderm: tetraploid rescue of Hnf-4(/) embryos. Development 124:279287[Abstract/Free Full Text]
- Li J, Ning G, Duncan SA 2000 Mammalian hepatocyte differentiation requires the transcription factor HNF-4
. Genes Dev 14:464474[Abstract/Free Full Text]
- Parviz F, Matullo C, Garrison WD, Savatski L, Adamson JW, Ning G, Kaestner KH, Rossi JM, Zaret KS, Duncan SA 2003 Hepatocyte nuclear factor 4
controls the development of a hepatic epithelium and liver morphogenesis. Nat Genet 34:292296[CrossRef][Medline]
- Hayhurst GP, Lee YH, Lambert G, Ward JM, Gonzalez FJ 2001 Hepatocyte nuclear factor 4
(nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol Cell Biol 21:13931403[Abstract/Free Full Text]
- Hadzopoulou-Cladaras M, Kistanova E, Evagelopoulou C, Zeng S, Cladaras C, Ladias JAA 1997 Functional domains of the nuclear receptor hepatocyte nuclear factor 4. J Biol Chem 272:539550[Abstract/Free Full Text]
- Bogan AA, Dallas-Yang Q, Ruse Jr MD, Maeda Y, Jiang G, Nepomuceno GL, Scanlan TS, Cohen FE, Sladek FM 2000 Analysis of protein dimerization and ligand binding of orphan receptor HNF4
. J Mol Biol 302:831851[CrossRef][Medline]
- Cheng DY, Kolls JK, Lei D, Noel RA 1997 In vivo and in vitro gene transfer and expression in rat intestinal epithelial cells by E1-deleted adenoviral vector. Hum Gene Ther 8:755764[Medline]
- Sauvaget D, Chauffeton V, Dugue-Pujol S, Kalopissis AD, Guillet-Deniau I, Foufelle F, Chambaz J, Leturque A, Cardot P, Ribeiro A 2004 In vitro transcriptional induction of the human apolipoprotein A-II gene by glucose. Diabetes 3:672678
- Kan H-Y, Georgopoulos S, Zanni M, Shkodrani A, Tzatsos A, Xie HX, Zannis VI 2004 Contribution of the hormone-response elements of the proximal ApoA-I promoter, ApoCIII enhancer, and C/EBP binding site of the proximal ApoA-I promoter to the hepatic and intestinal expression of the ApoA-I and ApoCIII genes in transgenic mice. Biochemistry 43:50845093[CrossRef][Medline]
- Lauer SJ, Simonet WS, Bucay N, De Silva HV, Taylor JM 1991 Tissue-specific expression of the human apolipoprotein A-IV gene in transgenic mice. Circulation 84:1390 (Abstract)
- Simon TC, Roberts LJJ, Gordon JI 1995 A 20-nucleotide element in the intestinal fatty acid binding protein gene modulates its cell lineage-specific, differentiation-dependent, and cephalocaudal patterns of expression in transgenic mice. Proc Natl Acad Sci USA 92:86858689[Abstract/Free Full Text]
- Cohn T, Simon TC, Roth KA, Birkenmeir EH, Gordon JI 1992 Use of transgenic mice to map cis-acting elements in the intestinal fatty acid binding protein gene (Fabpi) that control its cell lineage-specific and regional patterns of expression along the duodenal-colonic and crypt-villus axes of the gut epithelium. J Cell Biol 119:2744[Abstract]
- Simon TC, Roth KA, Gordon JI 1993 Use of transgenic mice to map cis-acting elements in the liver fatty acid-binding protein gene (Fabpl) that regulate its cell lineage-specific, differentiation-dependent, and spatial patterns of expression in the gut epithelium and in the liver acinus. J Biol Chem 268:1834518358[Abstract/Free Full Text]
- Markowitz AJ, Wu GD, Bierkenmeier EH, Traber PG 1993 The human sucrase-isomaltase gene directs complex patterns of gene expression in transgenic mice. Am J Physiol 265:G526G539
- Xu L, Glass CK, Rosenfeld MG 1999 Coactivator and corepressor complexes in nuclear receptor function. Curr Opin Genet Dev 9:140147[CrossRef][Medline]
- Kornberg R D, Lorch Y 1999 Chromatin-modifying and -remodeling complexes. Curr Opin Genet Dev 9:148151[CrossRef][Medline]
- Tou L, Liu Q, Shivdasani RA 2004 Regulation of mammalian epithelial differentiation and intestine development by class I histone deacetylases. Mol Cell Biol 24:31323139[Abstract/Free Full Text]
- Torres-Padilla ME, Sladek FM, Weiss MC 2002 Developmentally regulated N-terminal variants of the nuclear receptor hepatocyte nuclear factor 4
mediate multiple interactions through coactivator and corepressor-histone deacetylase complexes. J Biol Chem 277:4467744687[Abstract/Free Full Text]
- Torres-Padilla ME, Weiss MC 2003 Effects of interactions of hepatocyte nuclear factor 4
isoforms with coactivators and corepressors are promoter-specific. FEBS Lett 539:1923[CrossRef][Medline]
- Ruse Jr MD, Privalsky ML, Sladek FM 2002 Competitive cofactor recruitment by orphan receptor hepatocyte nuclear factor 4
1: modulation by the F domain. Mol Cell Biol 22:16261638[Abstract/Free Full Text]
- Le Beyec J, Ribeiro A, Schreider C, Chambaz J, Rousset M, Pinçon-Raymond M, Cardot P 1999 Illegitimate expression of apolipoprotein A-II in Caco-2 cells is due to chromatin organization. Exp Cell Res 247:373379[CrossRef][Medline]
- Perreault N, Beaulieu JF 1998 Primary cultures of fully differentiated and pure human intestinal epithelial cells. Exp Cell Res 245:3442[CrossRef][Medline]
- Flint N, Cove FL, Evans GS 1991 A low-temperature method for the isolation of small-intestinal epithelium along the crypt-villus axis. Biochem J 280:331334[Medline]
- Shapiro DJ, Sharp PA, Wahli WW, Keller MJ 1988 A high-efficiency HeLa cell nuclear transcription extract. DNA 7:4755[Medline]
- Ribeiro A, Pastier D, Kardassis D, Chambaz J, Cardot P 1999 Cooperative binding of upstream stimulatory factor and hepatic nuclear factor 4 drives the transcription of the human apolipoprotein A-II gene. J Biol Chem 274:12161225[Abstract/Free Full Text]
- Le Beyec J, Delers F, Jourdant F, Schreider C, Chambaz J, Cardot P, Pinçon-Raymond M 1997 A complete epithelial organization of Caco-2 cells induces I-FABP and potentializes apolipoprotein gene expression. Exp Cell Res 236:311320[CrossRef][Medline]
- Shimomura I, Shimano H, Horton JD, Goldstein JL, Brown MS 1997 Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J Clin Invest 99:838845[Abstract/Free Full Text]